Format

Send to

Choose Destination
Nat Rev Cancer. 2006 Sep;6(9):688-701. Epub 2006 Aug 10.

Polymer conjugates as anticancer nanomedicines.

Author information

1
Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK. Duncanr@cf.ac.uk

Abstract

The transfer of polymer-protein conjugates into routine clinical use, and the clinical development of polymer-anticancer-drug conjugates, both as single agents and as components of combination therapy, is establishing polymer therapeutics as one of the first classes of anticancer nanomedicines. There is growing optimism that ever more sophisticated polymer-based vectors will be a significant addition to the armoury currently used for cancer therapy.

PMID:
16900224
DOI:
10.1038/nrc1958
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center